LLYライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (2 7月 2024 @ 02:42):
Our systems believe the stock currently is overvalued by -0.04% compare to its pairs and should correct downwards.

Stats
本日の出来高	1.57M
平均出来高	2.64M
時価総額	868.84B
EPS	$2.49 ( Q1 \| 2024-04-30 )
次の収益日	( $2.65 ) 2024-08-13
Last Dividend	$1.300 ( 2024-05-15 )
Next Dividend	$0 ( N/A )
P/E	134.64 (Sector) 49.64 (Industry) 72.79
ATR14	$0.479 (0.05%)

ABBV -0.21%

AZN -0.13%

BMY -0.53%

CELG-RI 9.76%

GSK -0.16%

JNJ -0.17%

LLY 0.97%

MRK 3.38%

NVS 0.06%

OGN -1.21%

PFE 0.95%

Insider Trading

Date	Person	Action	Amount	type
2024-06-25	Lilly Endowment Inc	Sell	57 563	Common Stock
2024-06-25	Lilly Endowment Inc	Sell	62 127	Common Stock
2024-06-25	Lilly Endowment Inc	Sell	46 359	Common Stock
2024-06-25	Lilly Endowment Inc	Sell	4 019	Common Stock
2024-06-25	Lilly Endowment Inc	Sell	4 806	Common Stock

INSIDER POWER
-99.03
Last 100 transactions
Buy: 6 363 \| Sell: 1 297 151

相関 (AI algo v.1.1b): Overvalued: -0.04% $914.02 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: 0.23 (neutral)

短: 0.36 (neutral)

Signal:(30.422) Neutral

Eli Lilly and Co 相関

10 最も正の相関
SBXC	0.96
HAFN	0.948
BAH	0.941
POST	0.94
BRK-B	0.936
IHTA	0.935
PHD	0.935
APO	0.933
FRTY	0.932
BRK-A	0.927

10 最も負の相関
NVVE	-0.936
BYON	-0.927
FNGD	-0.922
QBTS	-0.92
SRFM	-0.918
RIV-PA	-0.915
RTO	-0.915
EP-PC	-0.91
WDS	-0.907
CCG	-0.907

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Eli Lilly and Co 相関 - 通貨/商品

-0.27
( neutral )

-0.15
( neutral )

-0.64
( weak negative )

-0.03
( neutral )

0.68
( moderate )

0.45
( neutral )

Eli Lilly and Co 財務諸表

Annual	2023
収益:	$34.12B
総利益:	$27.55B (80.73 %)
EPS:	$5.82

FY	2023
収益:	$34.12B
総利益:	$27.55B (80.73 %)
EPS:	$5.82

FY	2022
収益:	$28.54B
総利益:	$21.91B (76.77 %)
EPS:	$6.93

FY	2021
収益:	$28.32B
総利益:	$21.01B (74.18 %)
EPS:	$6.15

Financial Reports:

No articles found.

Eli Lilly and Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.980 (N/A)	$0.980 (N/A)	$1.130 (N/A)	$1.130 (N/A)	$2.26 (N/A)	$1.130 (N/A)	$1.300 (N/A)	$1.300 (N/A)	$0 (N/A)	$0 (N/A)

Eli Lilly and Co Dividend Information - Dividend King

Dividend Sustainability Score: 7.30 - good (72.96%) | Divividend Growth Potential Score: 6.18 - Stable (23.63%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0114	1972-08-07
Last Dividend	$1.300	2024-05-15
Next Dividend	$0	N/A
Payout Date	2024-06-10
Next Payout Date	N/A
# dividends	209	--
Total Paid Out	$63.28	--
Avg. Dividend % Per Year	1.27%	--
Score	5.03	--
Div. Sustainability Score	7.30
Div.Growth Potential Score	6.18
Div. Directional Score	6.74	--

Next Divdend (Est)
(2024-09-30)

$1.314 Estimate 74.85 %

Dividend Stability

1.00 Excellent

Dividend Score

5.03

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.0228	0.63%
1973	$0.0494	1.00%
1974	$0.0606	1.32%
1975	$0.0688	1.64%
1976	$0.0782	2.44%
1977	$0.0888	3.01%
1978	$0.103	4.37%
1979	$0.122	4.06%
1980	$0.137	3.79%
1981	$0.144	3.64%
1982	$0.162	4.67%
1983	$0.172	4.79%
1984	$0.186	5.00%
1985	$0.200	4.94%
1986	$0.225	3.28%
1987	$0.250	2.69%
1988	$0.288	2.88%
1989	$0.337	3.15%
1990	$0.412	2.40%
1991	$0.500	2.75%
1992	$0.552	2.60%
1993	$0.604	3.94%
1994	$0.624	4.20%
1995	$0.654	4.01%
1996	$0.684	2.47%
1997	$0.740	2.04%
1998	$0.800	1.16%
1999	$0.920	1.07%
2000	$1.040	1.59%
2001	$1.120	1.22%
2002	$1.240	1.58%
2003	$1.340	2.02%
2004	$1.420	1.99%
2005	$1.520	2.70%
2006	$1.600	2.79%
2007	$1.700	3.25%
2008	$1.880	3.58%
2009	$1.960	4.83%
2010	$1.960	5.47%
2011	$1.960	5.60%
2012	$1.960	4.69%
2013	$1.960	3.96%
2014	$1.960	3.86%
2015	$2.00	2.85%
2016	$2.04	2.46%
2017	$2.08	2.79%
2018	$2.25	2.66%
2019	$2.58	2.25%
2020	$2.96	2.24%
2021	$3.40	2.05%
2022	$3.92	1.44%
2023	$5.65	1.55%
2024	$2.60	0.44%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
15 May 2024	$1.300	06 May 2024	16 May 2024	10 Jun 2024
14 Feb 2024	$1.300	08 Dec 2023	15 Feb 2024	08 Mar 2024
14 Nov 2023	$1.130	01 Nov 2023	15 Nov 2023	08 Dec 2023
08 Sep 2023	$1.130	26 Jun 2023	08 Sep 2023	30 Nov -0001
14 Aug 2023	$1.130	26 Jun 2023	15 Aug 2023	08 Sep 2023
12 May 2023	$1.130	01 May 2023	15 May 2023	09 Jun 2023
14 Feb 2023	$1.130	12 Dec 2022	15 Feb 2023	10 Mar 2023
14 Nov 2022	$0.980	17 Oct 2022	15 Nov 2022	09 Dec 2022
12 Aug 2022	$0.980	27 Jun 2022	15 Aug 2022	09 Sep 2022
13 May 2022	$0.980	02 May 2022	16 May 2022	10 Jun 2022
14 Feb 2022	$0.980	13 Dec 2021	15 Feb 2022	10 Mar 2022
12 Nov 2021	$0.850	18 Oct 2021	15 Nov 2021	10 Dec 2021
12 Aug 2021	$0.850	29 Jun 2021	13 Aug 2021	10 Sep 2021
13 May 2021	$0.850	03 May 2021	14 May 2021	10 Jun 2021
11 Feb 2021	$0.850	14 Dec 2020	12 Feb 2021	10 Mar 2021
12 Nov 2020	$0.740	19 Oct 2020	13 Nov 2020	10 Dec 2020
13 Aug 2020	$0.740	15 Jul 2020	14 Aug 2020	10 Sep 2020
14 May 2020	$0.740	04 May 2020	15 May 2020	10 Jun 2020
13 Feb 2020	$0.740	16 Dec 2019	14 Feb 2020	10 Mar 2020
14 Nov 2019	$0.645	21 Oct 2019	15 Nov 2019	10 Dec 2019

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
ECC	Dividend Diamond	2024-07-11	Monthly	11	14.91%	9.72
BRW	Dividend Diamond	2024-06-11	Monthly	33	9.41%	9.26
VVR	Dividend Diamond	2024-06-18	Monthly	27	8.85%	9.19
FCT	Dividend Diamond	2024-06-03	Monthly	21	8.33%	9.14
PHK	Dividend Diamond	2024-06-13	Monthly	22	9.07%	9.13
SBR	Dividend Diamond	2024-06-17	Monthly	38	9.57%	9.10
XFLT	Dividend Diamond	2024-06-17	Monthly	8	10.49%	9.09
SRV	Dividend Royal	2024-07-16	Monthly	18	10.61%	9.04
FAM	Dividend Royal	2024-06-03	Monthly	20	8.07%	8.98
RA	Dividend Diamond	2024-06-11	Monthly	9	10.10%	8.93

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.171	1.500	6.58	9.88	[0 - 0.5]
returnOnAssetsTTM	0.0960	1.200	6.80	8.16	[0 - 0.3]
returnOnEquityTTM	0.535	1.500	5.16	7.74	[0.1 - 1]
payoutRatioTTM	0.688	-1.000	3.12	-3.12	[0 - 1]
currentRatioTTM	1.354	0.800	8.23	6.58	[1 - 3]
quickRatioTTM	0.677	0.800	-0.721	-0.577	[0.8 - 2.5]
cashRatioTTM	0.132	1.500	-0.376	-0.564	[0.2 - 2]
debtRatioTTM	0.410	-1.500	3.17	-4.75	[0 - 0.6]
interestCoverageTTM	17.51	1.000	4.62	4.62	[3 - 30]
operatingCashFlowPerShareTTM	4.08	2.00	8.64	10.00	[0 - 30]
freeCashFlowPerShareTTM	-4.22	2.00	-2.11	-4.22	[0 - 20]
debtEquityRatioTTM	2.05	-1.500	1.817	-2.73	[0 - 2.5]
grossProfitMarginTTM	0.809	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.230	1.000	7.39	7.39	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.140	1.000	-0.332	-0.332	[0.2 - 2]
assetTurnoverTTM	0.562	0.800	9.59	7.67	[0.5 - 2]
Total Score				7.30

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	132.86	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.535	2.50	6.89	7.74	[0.1 - 1.5]
freeCashFlowPerShareTTM	-4.22	2.00	-1.406	-4.22	[0 - 30]
dividendYielPercentageTTM	0.537	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.08	2.00	8.64	10.00	[0 - 30]
payoutRatioTTM	0.688	1.500	3.12	-3.12	[0 - 1]
pegRatioTTM	11.63	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.102	1.000	9.94	0	[0.1 - 0.5]
Total Score				6.18

Eli Lilly and Co Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Eli Lilly and Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.